Pradeep Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pradeep Kumar has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
Amit Kumar
Department of Neurology All India Institute of Medical Sciences New Delhi India
33 shared publications- Shubham Misra
Department of Neurology, Yale School of Medicine, New Haven, CT
33 shared publications - Kameshwar Prasad
All India Institute of Medical Sciences, New Delhi, India
27 shared publications Shubham Misra
Department of Neurology, Yale University, New Haven, CT, USA
16 shared publications- Ram Sagar
Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, USA
15 shared publications - Deepti Vibha
Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
13 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wolters Kluwer Health in Acta Neurologica Taiwanica
- Vol. 35 (4) , 188-200
Comparative Effectiveness of Mechanical Thrombectomy Techniques for Large Vessel Occlusion Stroke: A Network Meta-analysis of Randomized Controlled Trials
Background: Mechanical thrombectomy (MT) is a key intervention for acute ischemic stroke due to large vessel occlusion (LVO). Various MT strategies – stent retriever (SR), aspiration (Asp), and their combination (SR + Asp) – are widely used, but the optimal approach remains unclear. Objectives: This network meta-analysis (NMA) aimed to compare the efficacy and safety of these techniques using evidence from randomized controlled trials (RCTs). Materials and Methods: A Bayesian NMA was conducted, including RCTs evaluating different MT techniques in LVO-related stroke. The primary outcome was successful recanalization (thrombolysis in cerebral infarction ≥2b) and good functional outcome (modified Rankin Scale ≤2 at 90 days). Secondary outcomes included all-cause mortality at 90 days and symptomatic intracranial hemorrhage (sICH) within 24 h. Odds ratios (ORs) with 95% credible intervals (CrIs) were calculated using a Bayesian random-effects model. Results: Twenty-seven RCTs were analyzed. Within the current evidence network, SR demonstrated the highest probability of good functional recovery (OR = 2.27; 95% CrI: 1.72-3.02) and successful recanalization (OR = 13.6; 95% CrI: 3.12-75.0). SR + Asp demonstrated the highest probability of reducing 90-day mortality (OR = 0.771; 95% CrI: 0.638-0.929). Rates of sICH were broadly comparable across thrombectomy strategies, although SR and SR + Asp showed higher estimated odds than standard treatment (ST). Conclusions: This NMA suggests that SR thrombectomy has the highest probability of achieving successful recanalization and favourable functional outcomes, whereas combined (SR + Asp) showed the highest probability of reducing mortality within the current evidence network. These probability-based rankings should be interpreted cautiously because they were derived from a heterogeneous network with limited direct head-to-head comparisons. Future adequately powered randomized trials directly comparing thrombectomy strategies are required before definitive recommendations can be made.
- 29 October 2026
- Published by Wolters Kluwer Health in Acta Neurologica Taiwanica
- Vol. 35 (4) , 188-200
Open AccessComparative Effectiveness of Mechanical Thrombectomy Techniques for Large Vessel Occlusion Stroke: A Network Meta-analysis of Randomized Controlled Trials
Background: Mechanical thrombectomy (MT) is a key intervention for acute ischemic stroke due to large vessel occlusion (LVO). Various MT strategies – stent retriever (SR), aspiration (Asp), and their combination (SR + Asp) – are widely used, but the optimal approach remains unclear. Objectives: This network meta-analysis (NMA) aimed to compare the efficacy and safety of these techniques using evidence from randomized controlled trials (RCTs). Materials and Methods: A Bayesian NMA was conducted, including RCTs evaluating different MT techniques in LVO-related stroke. The primary outcome was successful recanalization (thrombolysis in cerebral infarction ≥2b) and good functional outcome (modified Rankin Scale ≤2 at 90 days). Secondary outcomes included all-cause mortality at 90 days and symptomatic intracranial hemorrhage (sICH) within 24 h. Odds ratios (ORs) with 95% credible intervals (CrIs) were calculated using a Bayesian random-effects model. Results: Twenty-seven RCTs were analyzed. Within the current evidence network, SR demonstrated the highest probability of good functional recovery (OR = 2.27; 95% CrI: 1.72-3.02) and successful recanalization (OR = 13.6; 95% CrI: 3.12-75.0). SR + Asp demonstrated the highest probability of reducing 90-day mortality (OR = 0.771; 95% CrI: 0.638-0.929). Rates of sICH were broadly comparable across thrombectomy strategies, although SR and SR + Asp showed higher estimated odds than standard treatment (ST). Conclusions: This NMA suggests that SR thrombectomy has the highest probability of achieving successful recanalization and favourable functional outcomes, whereas combined (SR + Asp) showed the highest probability of reducing mortality within the current evidence network. These probability-based rankings should be interpreted cautiously because they were derived from a heterogeneous network with limited direct head-to-head comparisons. Future adequately powered randomized trials directly comparing thrombectomy strategies are required before definitive recommendations can be made.
- Open Access
Evolving Epidemiology of Stroke in India: Burden, Inequalities, and Risk Factors from 1990 to 2023 with Projections to 2035
Background and Purpose: Stroke continues to be one of the major causes of death and long-term disability worldwide, with a greater impact in low- and middle-income countries. In India, there is limited evidence examining stroke burden and its changes over time and across regions. Therefore, we aimed to assess the burden of stroke in India from 1990 to 2023 using the latest data from the Global Burden of Disease (GBD) Study, along with projections up to 2035. Methods: We used estimates from the GBD 2023 study to examine stroke incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in India from 1990 to 2023. Age-standardized rates were analyzed to understand how these measures have changed over time. We also conducted state-level analyses to explore regional differences in stroke burden. The contributions of all major modifiable risk factors were assessed using population-attributable fractions. In addition, we projected future trends in stroke burden up to 2035. Results: From 1990 to 2023, the percentage change in overall stroke burden in India showed minimal variation across key indicators. Incidence remained largely stable (0.00% [–0.04 to 0.05]), while prevalence showed a slight increase (0.06% [0.03 to 0.10]). Mortality (–0.11% [–0.36 to 0.20]) and DALYs (–0.17% [–0.38 to 0.12]) demonstrated modest declines over the study period. Notable regional disparities were evident, with states such as Chhattisgarh, Assam, and Jharkhand bearing the highest burden. High systolic blood pressure remained the leading risk factor in 2023, contributing the largest share of stroke-related deaths, followed by dietary risks, air pollution, tobacco use, and high body mass index. Future projections indicate that by 2035, stroke prevalence is likely to increase, while incidence, mortality, and DALYs are expected to show only modest changes. Conclusions: Stroke remains a major and growing public health challenge in India with a continuing increase in burden despite slight improvements in age-standardized rates over time. Addressing this challenge will require stronger prevention efforts, better control of key risk factors, and focused strategies to reduce regional disparities in stroke burden nationwide.
Open AccessEvolving Epidemiology of Stroke in India: Burden, Inequalities, and Risk Factors from 1990 to 2023 with Projections to 2035
Background and Purpose: Stroke continues to be one of the major causes of death and long-term disability worldwide, with a greater impact in low- and middle-income countries. In India, there is limited evidence examining stroke burden and its changes over time and across regions. Therefore, we aimed to assess the burden of stroke in India from 1990 to 2023 using the latest data from the Global Burden of Disease (GBD) Study, along with projections up to 2035. Methods: We used estimates from the GBD 2023 study to examine stroke incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in India from 1990 to 2023. Age-standardized rates were analyzed to understand how these measures have changed over time. We also conducted state-level analyses to explore regional differences in stroke burden. The contributions of all major modifiable risk factors were assessed using population-attributable fractions. In addition, we projected future trends in stroke burden up to 2035. Results: From 1990 to 2023, the percentage change in overall stroke burden in India showed minimal variation across key indicators. Incidence remained largely stable (0.00% [–0.04 to 0.05]), while prevalence showed a slight increase (0.06% [0.03 to 0.10]). Mortality (–0.11% [–0.36 to 0.20]) and DALYs (–0.17% [–0.38 to 0.12]) demonstrated modest declines over the study period. Notable regional disparities were evident, with states such as Chhattisgarh, Assam, and Jharkhand bearing the highest burden. High systolic blood pressure remained the leading risk factor in 2023, contributing the largest share of stroke-related deaths, followed by dietary risks, air pollution, tobacco use, and high body mass index. Future projections indicate that by 2035, stroke prevalence is likely to increase, while incidence, mortality, and DALYs are expected to show only modest changes. Conclusions: Stroke remains a major and growing public health challenge in India with a continuing increase in burden despite slight improvements in age-standardized rates over time. Addressing this challenge will require stronger prevention efforts, better control of key risk factors, and focused strategies to reduce regional disparities in stroke burden nationwide.
- Open Access
- 15 May 2026
- Published by Frontiers Media SA in Frontiers in Stroke
- Vol. 5, 1816483
Association of hyponatremia and risk of in-hospital mortality in patients with acute stroke: a systematic review and meta-analysis
Objective: Hyponatremia is among the most common electrolyte disturbances in acute stroke and has been increasingly recognized as a potential predictor of early complications. We aimed to evaluate whether hyponatremia on admission is associated with increased in-hospital mortality in patients with acute ischemic stroke (IS) and hemorrhagic stroke (HS). Methods: We conducted a comprehensive systematic search of PubMed, Scopus, and Embase to identify relevant studies published between 1st January 2000 and 30th October 2025. Eligible studies included patients with acute stroke, reported admission serum sodium levels, and compared outcomes between hyponatremic and normonatremic groups. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model. Subgroup analyses were performed based on stroke type. Results: Seventeen studies involving patients assessed within 24–72 h of stroke onset were included. Hyponatremia on admission was significantly associated with higher in-hospital mortality (RR 1.41, 95% CI 1.14–1.74). The association remained significant in ischemic stroke (RR 1.29, 95% CI 1.16–1.42) and in studies including mixed IS and HS populations (RR 1.59, 95% CI 1.19–2.12). No significant association was observed in hemorrhagic stroke alone (RR 1.47, 95% CI 0.70–3.10). Between-study heterogeneity was moderate ( I 2 = 58.9%, p < 0.001). Funnel plot assessment suggested no significant publication bias. Conclusions: Hyponatremia on admission is associated with increased in-hospital mortality in acute stroke, particularly in ischemic stroke. Early identification and management of hyponatremia may have prognostic and therapeutic relevance in acute stroke care. Systematic Review Registration: PROSPERO: CRD420251110001.
- 15 May 2026
- Published by Frontiers Media SA in Frontiers in Stroke
- Vol. 5, 1816483
Open AccessAssociation of hyponatremia and risk of in-hospital mortality in patients with acute stroke: a systematic review and meta-analysis
Objective: Hyponatremia is among the most common electrolyte disturbances in acute stroke and has been increasingly recognized as a potential predictor of early complications. We aimed to evaluate whether hyponatremia on admission is associated with increased in-hospital mortality in patients with acute ischemic stroke (IS) and hemorrhagic stroke (HS). Methods: We conducted a comprehensive systematic search of PubMed, Scopus, and Embase to identify relevant studies published between 1st January 2000 and 30th October 2025. Eligible studies included patients with acute stroke, reported admission serum sodium levels, and compared outcomes between hyponatremic and normonatremic groups. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model. Subgroup analyses were performed based on stroke type. Results: Seventeen studies involving patients assessed within 24–72 h of stroke onset were included. Hyponatremia on admission was significantly associated with higher in-hospital mortality (RR 1.41, 95% CI 1.14–1.74). The association remained significant in ischemic stroke (RR 1.29, 95% CI 1.16–1.42) and in studies including mixed IS and HS populations (RR 1.59, 95% CI 1.19–2.12). No significant association was observed in hemorrhagic stroke alone (RR 1.47, 95% CI 0.70–3.10). Between-study heterogeneity was moderate ( I 2 = 58.9%, p < 0.001). Funnel plot assessment suggested no significant publication bias. Conclusions: Hyponatremia on admission is associated with increased in-hospital mortality in acute stroke, particularly in ischemic stroke. Early identification and management of hyponatremia may have prognostic and therapeutic relevance in acute stroke care. Systematic Review Registration: PROSPERO: CRD420251110001.
- Open Access
The Great Recanalization Debate in Acute Ischemic Stroke: Direct Thrombectomy versus Bridging Therapy—A Meta-analysis of Randomized Controlled Trials
Background: Endovascular thrombectomy (EVT) is the standard of care for acute ischemic stroke caused by large-vessel occlusion. However, the additional benefit of intravenous thrombolysis (IVT) before EVT remains controversial. This systematic review and meta-analysis evaluated the efficacy and safety of bridging therapy (EVT plus IVT) compared with EVT alone. Methods: This systematic review and meta-analysis was conducted according to PRISMA 2020 and Cochrane Handbook recommendations and prospectively registered in PROSPERO. PubMed, EMbase, Scopus, and the Cochrane Library were searched for randomized controlled trials published between 1 st January 2015 and 30 th April 2026 comparing EVT plus IVT versus EVT alone in acute ischemic stroke. Random-effects meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs). Primary outcomes included functional independence at 90 days and successful recanalization. Secondary outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality. Results: Eleven randomized controlled trials involving 4,419 patients were included in the meta-analysis. Compared with EVT alone, bridging therapy was associated with significantly better functional independence at 90 days (OR=1.25; 95% CI: 1.02–1.53). Patients receiving EVT plus IVT also demonstrated a trend toward higher rates of successful recanalization (OR=1.25; 95% CI: 0.95–1.64) and lower 90-day mortality (OR=0.84; 95% CI: 0.67–1.04). The risk of sICH was comparable between the two treatment strategies (OR=1.07; 95% CI: 0.81–1.40). Overall, the certainty of evidence was rated as moderate. Conclusions: Bridging therapy before EVT may improve functional outcomes and recanalization without increasing sICH, supporting its use as a reasonable treatment strategy in eligible patients with acute ischemic stroke.
Open AccessThe Great Recanalization Debate in Acute Ischemic Stroke: Direct Thrombectomy versus Bridging Therapy—A Meta-analysis of Randomized Controlled Trials
Background: Endovascular thrombectomy (EVT) is the standard of care for acute ischemic stroke caused by large-vessel occlusion. However, the additional benefit of intravenous thrombolysis (IVT) before EVT remains controversial. This systematic review and meta-analysis evaluated the efficacy and safety of bridging therapy (EVT plus IVT) compared with EVT alone. Methods: This systematic review and meta-analysis was conducted according to PRISMA 2020 and Cochrane Handbook recommendations and prospectively registered in PROSPERO. PubMed, EMbase, Scopus, and the Cochrane Library were searched for randomized controlled trials published between 1 st January 2015 and 30 th April 2026 comparing EVT plus IVT versus EVT alone in acute ischemic stroke. Random-effects meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs). Primary outcomes included functional independence at 90 days and successful recanalization. Secondary outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality. Results: Eleven randomized controlled trials involving 4,419 patients were included in the meta-analysis. Compared with EVT alone, bridging therapy was associated with significantly better functional independence at 90 days (OR=1.25; 95% CI: 1.02–1.53). Patients receiving EVT plus IVT also demonstrated a trend toward higher rates of successful recanalization (OR=1.25; 95% CI: 0.95–1.64) and lower 90-day mortality (OR=0.84; 95% CI: 0.67–1.04). The risk of sICH was comparable between the two treatment strategies (OR=1.07; 95% CI: 0.81–1.40). Overall, the certainty of evidence was rated as moderate. Conclusions: Bridging therapy before EVT may improve functional outcomes and recanalization without increasing sICH, supporting its use as a reasonable treatment strategy in eligible patients with acute ischemic stroke.
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (2) , e200602
Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis
Seronegative autoimmune encephalitis (AE), characterized by the absence of known neuronal autoantibodies despite meeting clinical criteria, presents significant diagnostic and therapeutic challenges. Although immunotherapy is frequently used, long-term outcomes in this population remain poorly characterized. This systematic review and meta-analysis aims to synthesize evidence on long-term outcomes in seronegative AE, focusing on functional status, seizure burden, cognitive impairment, relapses, immunotherapy practices, and prognostic indicators. We included studies involving patients 12 years or older diagnosed with antibody-negative probable AE (ANPRA), possible AE, or definite limbic encephalitis (LE) with negative neuronal antibodies according to Graus et al. (2016), with a minimum median follow-up of 6 months. Nineteen studies, predominantly retrospective cohorts with moderate risk of bias, met the inclusion criteria. The pooled proportion of patients achieving favorable functional outcomes (modified Rankin Scale 0-2) was 65% (95% CI 51% - 78%; I2 = 88.1%; 12 studies, n = 782). Outcomes differed by seronegative subtype, with better functional recovery in seronegative LE (73%; 95% CI 45%-90%; 6 studies, n = 95) compared with ANPRA (47%; 95% CI 38%-55%; 5 studies, n = 277; p = 0.005). When compared with seropositive AE (n = 466), seronegative patients (n = 373) demonstrated comparable odds of favorable functional outcomes (odds ratio 0.50; 95% CI 0.19-1.31; p = 0.16) but had a significantly higher risk of persistent seizures (risk ratio 1.66; 95% CI 1.01-2.72; p = 0.04). The pooled relapse proportion among seronegative patients was 17% (95% CI 11%-26%; 7 studies, n = 350), with no significant difference by serostatus. Residual disability assessed using the Clinical Assessment Scale in Autoimmune Encephalitis suggested mild persistent impairment (mean score 3.11; 95% CI 1.79-4.43; 5 studies, n = 409). Owing to heterogeneity and inconsistent reporting, meta-analysis of cognitive outcomes, immunotherapy strategies, and RAPID (Refractory status epilepticus, Age ≥ 60 years, Probable AE, Infratentorial involvement, Delayed immunotherapy ≥ 1 month) scores was not feasible; narrative synthesis suggested persistent cognitive deficits and lower utilization of second-line immunotherapy in seronegative cohorts. Seronegative AE is associated with heterogeneous outcomes, with antibody-negative LE demonstrating better recovery than ANPRA. Subtype-specific variability and elevated seizure burden highlight the need for individualized management, timely diagnosis, structured follow-up, and well-designed prospective research.
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (2) , e200602
Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis
Seronegative autoimmune encephalitis (AE), characterized by the absence of known neuronal autoantibodies despite meeting clinical criteria, presents significant diagnostic and therapeutic challenges. Although immunotherapy is frequently used, long-term outcomes in this population remain poorly characterized. This systematic review and meta-analysis aims to synthesize evidence on long-term outcomes in seronegative AE, focusing on functional status, seizure burden, cognitive impairment, relapses, immunotherapy practices, and prognostic indicators. We included studies involving patients 12 years or older diagnosed with antibody-negative probable AE (ANPRA), possible AE, or definite limbic encephalitis (LE) with negative neuronal antibodies according to Graus et al. (2016), with a minimum median follow-up of 6 months. Nineteen studies, predominantly retrospective cohorts with moderate risk of bias, met the inclusion criteria. The pooled proportion of patients achieving favorable functional outcomes (modified Rankin Scale 0-2) was 65% (95% CI 51% - 78%; I2 = 88.1%; 12 studies, n = 782). Outcomes differed by seronegative subtype, with better functional recovery in seronegative LE (73%; 95% CI 45%-90%; 6 studies, n = 95) compared with ANPRA (47%; 95% CI 38%-55%; 5 studies, n = 277; p = 0.005). When compared with seropositive AE (n = 466), seronegative patients (n = 373) demonstrated comparable odds of favorable functional outcomes (odds ratio 0.50; 95% CI 0.19-1.31; p = 0.16) but had a significantly higher risk of persistent seizures (risk ratio 1.66; 95% CI 1.01-2.72; p = 0.04). The pooled relapse proportion among seronegative patients was 17% (95% CI 11%-26%; 7 studies, n = 350), with no significant difference by serostatus. Residual disability assessed using the Clinical Assessment Scale in Autoimmune Encephalitis suggested mild persistent impairment (mean score 3.11; 95% CI 1.79-4.43; 5 studies, n = 409). Owing to heterogeneity and inconsistent reporting, meta-analysis of cognitive outcomes, immunotherapy strategies, and RAPID (Refractory status epilepticus, Age ≥ 60 years, Probable AE, Infratentorial involvement, Delayed immunotherapy ≥ 1 month) scores was not feasible; narrative synthesis suggested persistent cognitive deficits and lower utilization of second-line immunotherapy in seronegative cohorts. Seronegative AE is associated with heterogeneous outcomes, with antibody-negative LE demonstrating better recovery than ANPRA. Subtype-specific variability and elevated seizure burden highlight the need for individualized management, timely diagnosis, structured follow-up, and well-designed prospective research.
- Open Access
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Stroke
- Vol. 5, 1684121
The APOE paradox: divergent genetic influences on hemorrhagic stroke risk—A meta-analysis
Background: Apolipoprotein E (APOE) regulates lipid metabolism and neuronal repair, yet its alleles show contrasting effects on hemorrhagic stroke (HS) risk. While some variants increase susceptibility, others appear protective, leading to inconsistent findings. This meta-analysis systematically evaluates the APOE-HS association to clarify its role in stroke pathophysiology. Methods: A comprehensive literature search was conducted across multiple databases up to January 31, 2025, using the keywords: (“Apolipoprotein E” OR “APOE” OR “APOE genotype”) AND (“Single Nucleotide Polymorphisms” OR “SNP”) AND (“Hemorrhagic stroke” OR “HS” OR “Intracerebral Hemorrhage” OR “ICH”). The APOE ε3/ε3 genotype served as the reference genotype in all studies, and only those studies with ε3/ε3 genotype were included in the analysis. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated, and statistical analyses were performed using STATA version 13.0 (StataCorp LLC, College Station, Texas, United States). Results: A total of 24 studies comprising 8,269 HS patients and 26,321 controls were included. Meta-analysis revealed a significant association of APOE ε2/ε2 (OR = 1.93, 95% CI = 1.32–2.81), ε4/ε4 (OR = 1.60, 95% CI = 1.21–2.13), ε2/ε4 (OR = 1.81, 95% CI = 1.34–2.44), ε2 (OR = 1.23, 95% CI = 1.12–1.35), and ε4 (OR = 1.31, 95% CI = 1.14–1.51) with an increased risk of HS. Conclusion: Our findings suggest that APOE ε2/ε2, ε2/ε4, ε2, and ε4/ε4 genotypes and the ε4 allele are associated with an elevated risk of HS. These results highlight the potential role of APOE genotypes in HS susceptibility and warrant further investigation.
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Stroke
- Vol. 5, 1684121
Open AccessThe APOE paradox: divergent genetic influences on hemorrhagic stroke risk—A meta-analysis
Background: Apolipoprotein E (APOE) regulates lipid metabolism and neuronal repair, yet its alleles show contrasting effects on hemorrhagic stroke (HS) risk. While some variants increase susceptibility, others appear protective, leading to inconsistent findings. This meta-analysis systematically evaluates the APOE-HS association to clarify its role in stroke pathophysiology. Methods: A comprehensive literature search was conducted across multiple databases up to January 31, 2025, using the keywords: (“Apolipoprotein E” OR “APOE” OR “APOE genotype”) AND (“Single Nucleotide Polymorphisms” OR “SNP”) AND (“Hemorrhagic stroke” OR “HS” OR “Intracerebral Hemorrhage” OR “ICH”). The APOE ε3/ε3 genotype served as the reference genotype in all studies, and only those studies with ε3/ε3 genotype were included in the analysis. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated, and statistical analyses were performed using STATA version 13.0 (StataCorp LLC, College Station, Texas, United States). Results: A total of 24 studies comprising 8,269 HS patients and 26,321 controls were included. Meta-analysis revealed a significant association of APOE ε2/ε2 (OR = 1.93, 95% CI = 1.32–2.81), ε4/ε4 (OR = 1.60, 95% CI = 1.21–2.13), ε2/ε4 (OR = 1.81, 95% CI = 1.34–2.44), ε2 (OR = 1.23, 95% CI = 1.12–1.35), and ε4 (OR = 1.31, 95% CI = 1.14–1.51) with an increased risk of HS. Conclusion: Our findings suggest that APOE ε2/ε2, ε2/ε4, ε2, and ε4/ε4 genotypes and the ε4 allele are associated with an elevated risk of HS. These results highlight the potential role of APOE genotypes in HS susceptibility and warrant further investigation.
- Open Access
- 10 December 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Effect of different Iron-Folic acid (IFA) formulations, doses, and frequencies on pregnancy and neonatal outcomes compared to multiple micronutrients (MMN) among pregnant women: a systematic review and meta-analysis
Iron-Folic Acid (IFA) supplementation during pregnancy is widely recommended to prevent maternal anemia and improve birth outcomes. However, the optimal fo
- 10 December 2025
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessEffect of different Iron-Folic acid (IFA) formulations, doses, and frequencies on pregnancy and neonatal outcomes compared to multiple micronutrients (MMN) among pregnant women: a systematic review and meta-analysis
Iron-Folic Acid (IFA) supplementation during pregnancy is widely recommended to prevent maternal anemia and improve birth outcomes. However, the optimal fo
- Open Access
- 9 December 2025
- Published by Elsevier in Indian Heart Journal
- Vol. 78 (2) , 100-111
Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: A network meta-analysis of randomized trials
- 9 December 2025
- Published by Elsevier in Indian Heart Journal
- Vol. 78 (2) , 100-111
Open AccessDirect oral anticoagulants for stroke prevention in patients with atrial fibrillation: A network meta-analysis of randomized trials
- Open Access
Mechanical Thrombectomy for Distal Medium Vessel Occlusions in Acute Ischemic Stroke: A Systematic review and Meta-Analysis of Randomized Controlled Trials
Background: Mechanical thrombectomy (MT) is established as standard care for acute ischemic stroke (AIS) due to large vessel occlusion, but its role in distal medium vessel occlusions (DMVOs) remains uncertain. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of MT vs best medical management (BMM) in patients with DMVO-related AIS. Methods: A systematic search of PubMed, Embase, Scopus, and the Cochrane Library was conducted through February 2025 to identify randomized controlled trials (RCTs) comparing MT to BMM in patients with DMVO. The primary outcome was functional independence at 90 days (modified Rankin Scale [mRS] 0–2). Secondary outcomes included excellent outcome (mRS 0–1), symptomatic intracerebral haemorrhage (sICH), all-cause mortality, and serious adverse events. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model and heterogeneity was assessed with the I 2 statistic. Results: Three RCTs involving 1,222 patients were included; 601 received MT and 623 received BMM. MT was not associated with improved functional independence at 90 days (OR, 0.81; 95% CI, 0.49–1.32). The risk of sICH was higher in the MT group (OR, 2.33; 95% CI, 1.31– 4.13), while mortality rates were similar (OR, 1.33; 95% CI, 0.90–1.98). In a subgroup of 466 patients with M2 occlusions, MT showed no significant benefit over BMM (OR, 0.93; 95% CI, 0.72–1.19). Conclusions: MT did not improve functional outcomes in patients with DMVO, including those with M2 occlusions, and was associated with a higher risk of sICH. Further trials are warranted to refine patient selection and procedural approaches in this population.
Open AccessMechanical Thrombectomy for Distal Medium Vessel Occlusions in Acute Ischemic Stroke: A Systematic review and Meta-Analysis of Randomized Controlled Trials
Background: Mechanical thrombectomy (MT) is established as standard care for acute ischemic stroke (AIS) due to large vessel occlusion, but its role in distal medium vessel occlusions (DMVOs) remains uncertain. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of MT vs best medical management (BMM) in patients with DMVO-related AIS. Methods: A systematic search of PubMed, Embase, Scopus, and the Cochrane Library was conducted through February 2025 to identify randomized controlled trials (RCTs) comparing MT to BMM in patients with DMVO. The primary outcome was functional independence at 90 days (modified Rankin Scale [mRS] 0–2). Secondary outcomes included excellent outcome (mRS 0–1), symptomatic intracerebral haemorrhage (sICH), all-cause mortality, and serious adverse events. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model and heterogeneity was assessed with the I 2 statistic. Results: Three RCTs involving 1,222 patients were included; 601 received MT and 623 received BMM. MT was not associated with improved functional independence at 90 days (OR, 0.81; 95% CI, 0.49–1.32). The risk of sICH was higher in the MT group (OR, 2.33; 95% CI, 1.31– 4.13), while mortality rates were similar (OR, 1.33; 95% CI, 0.90–1.98). In a subgroup of 466 patients with M2 occlusions, MT showed no significant benefit over BMM (OR, 0.93; 95% CI, 0.72–1.19). Conclusions: MT did not improve functional outcomes in patients with DMVO, including those with M2 occlusions, and was associated with a higher risk of sICH. Further trials are warranted to refine patient selection and procedural approaches in this population.
- Open Access
Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Global Synthesis of Randomized Evidence through Network Meta-Analysis
Background and Objectives Direct oral anticoagulants (DOACs) have become preferred alternatives to vitamin K antagonists (VKAs) for stroke prevention in both valvular (VAF) and non-valvular atrial fibrillation (NVAF). However, comparative evidence on the relative efficacy and safety of different DOACs remains limited. This network meta-analysis aimed to systematically assess and compare the efficacy and safety of various DOACs versus VKAs in preventing stroke and related outcomes among patients with AF. Methods A comprehensive literature search of PubMed, EMbase, and the Cochrane Library was conducted for randomized controlled trials (RCTs) published up to October 31, 2024. A Bayesian network meta-analysis was performed using odds ratios (ORs) with corresponding 95% credible intervals (CrIs). Results A total of 43 RCTs were included, comprising 30 on VAF and 13 on NVAF. Compared to VKA, apixaban (OR = 0.81; 95% CrI: 0.73 to 0.91), dabigatran (OR = 0.77; 95% CrI: 0.68 to 0.87), and rivaroxaban (OR = 0.87; 95% CrI: 0.79 to 0.96) were significantly associated with reduced risk of IS/SE, while edoxaban showed a non-significant effect. All DOACs were significantly superior to VKA in reducing the risk of HS. For major bleeding, apixaban (OR = 0.69; 95% CrI: 0.55 to 0.88) showed a significant advantage over VKA, while dabigatran and rivaroxaban were associated with non-significant increases. In terms of all-cause mortality, apixaban significantly reduced risk in NVAF (OR = 0.88; 95% CrI: 0.82 to 0.96), whereas dabigatran, edoxaban, and rivaroxaban showed non-significant associations. In VAF, neither dabigatran nor rivaroxaban demonstrated a significant impact on mortality. Conclusion This network meta-analysis suggests that apixaban and dabigatran are associated with significantly better outcomes in terms of reducing ischemic and hemorrhagic events, major bleeding, and mortality compared to VKAs, particularly in NVAF patients. Edoxaban and rivaroxaban showed favourable but generally non-significant associations. These findings support the use of apixaban and dabigatran for stroke prevention in patients with AF.
Open AccessDirect Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Global Synthesis of Randomized Evidence through Network Meta-Analysis
Background and Objectives Direct oral anticoagulants (DOACs) have become preferred alternatives to vitamin K antagonists (VKAs) for stroke prevention in both valvular (VAF) and non-valvular atrial fibrillation (NVAF). However, comparative evidence on the relative efficacy and safety of different DOACs remains limited. This network meta-analysis aimed to systematically assess and compare the efficacy and safety of various DOACs versus VKAs in preventing stroke and related outcomes among patients with AF. Methods A comprehensive literature search of PubMed, EMbase, and the Cochrane Library was conducted for randomized controlled trials (RCTs) published up to October 31, 2024. A Bayesian network meta-analysis was performed using odds ratios (ORs) with corresponding 95% credible intervals (CrIs). Results A total of 43 RCTs were included, comprising 30 on VAF and 13 on NVAF. Compared to VKA, apixaban (OR = 0.81; 95% CrI: 0.73 to 0.91), dabigatran (OR = 0.77; 95% CrI: 0.68 to 0.87), and rivaroxaban (OR = 0.87; 95% CrI: 0.79 to 0.96) were significantly associated with reduced risk of IS/SE, while edoxaban showed a non-significant effect. All DOACs were significantly superior to VKA in reducing the risk of HS. For major bleeding, apixaban (OR = 0.69; 95% CrI: 0.55 to 0.88) showed a significant advantage over VKA, while dabigatran and rivaroxaban were associated with non-significant increases. In terms of all-cause mortality, apixaban significantly reduced risk in NVAF (OR = 0.88; 95% CrI: 0.82 to 0.96), whereas dabigatran, edoxaban, and rivaroxaban showed non-significant associations. In VAF, neither dabigatran nor rivaroxaban demonstrated a significant impact on mortality. Conclusion This network meta-analysis suggests that apixaban and dabigatran are associated with significantly better outcomes in terms of reducing ischemic and hemorrhagic events, major bleeding, and mortality compared to VKAs, particularly in NVAF patients. Edoxaban and rivaroxaban showed favourable but generally non-significant associations. These findings support the use of apixaban and dabigatran for stroke prevention in patients with AF.